



ABHAVA PRATINIDHI DRAVYA AND APAMISHRANA DRAVYA: A COMPREHENSIVE CRITICAL REVIEW

Dr. Ashwini B S¹, Dr. Shashikala B Bani²

PG Scholar¹, HOD and Guide², Department of Dravyaguna

Rajiv Gandhi Education Society's Ayurveda Medical College, Hospital & P.G Studies and Research Centre

ABSTRACT

Ayurveda emphasizes the importance of authentic medicinal substances (Dravya) in achieving therapeutic success. Due to ecological imbalance, overexploitation, seasonal variation, and geographical limitations, several classical drugs have become scarce. The Ayurvedic concept of Abhava Pratinidhi Dravya provides a scientific framework for substitution of unavailable drugs with pharmacologically similar alternatives. In contrast, Apamishrana Dravya refers to adulteration, which compromises drug quality and safety. This article elaborates classical references with original shlokas, need, types, clinical relevance, differences between substitution and adulteration, and quality control measures.

INTRODUCTION

In Ayurveda, Dravya is one of the four essential components of treatment. The qualities of an ideal drug include Bahuta (abundance), Yogyata (suitability), Aneka Vidha Kalpana (adaptability for formulations), and Sampat (therapeutic potency).¹

CLASSICAL DEFINITION OF PRATINIDHI DRAVYA

प्रतिनिधीयते सदृशीक्रियते इति प्रतिनिधिः ॥

The term Pratinidhi means that which performs similar action. Thus, a substitute drug must possess comparable pharmacodynamic properties.²

त्रयंस्त्रयशदिति प्रोक्ता वर्गा शोधनादयः ।

युज्यात्तद्विधमन्यच्च द्रव्यं जहात्ययोगकम् ॥ (अ.ह.सू.15/46)

Ashtanga Hridaya explains that drugs belonging to similar therapeutic groups may be substituted when unavailable.³

योज्यमेकतराभावे परं वैद्येन जानता ।

रसवीर्यविपाकाद्यैः समं द्रव्यं विचिन्त्य च ॥176 ॥

युज्याद्विधमन्यच्च द्रव्याणां तु रसादिवित् ॥177 ॥

अनुक्तमपि युक्तं यद्योजयेत् तद्रसादिवित् ॥178 ॥ (भा.प्र.नि.6/176-178)

Bhavaprakasha clearly states that a knowledgeable physician may select substitute drugs based on similarity in Rasa, Virya, Vipaka, and other pharmacological properties.⁴

कदाचिद्द्रव्यमेकं वा योगे यत्र न लभ्यते ।

तत्तद्गुणयुतं द्रव्यं परं तेनोपयोजयेत् ॥ (भै.र. 4/57)

Bhaishajya Ratnavali states that if a drug is unavailable in a formulation, another drug possessing similar qualities may be used without affecting efficacy.⁵

NEED FOR SUBSTITUTION

Substitution becomes necessary due to non-availability of genuine drugs, seasonal variation, high cost, geographical distribution, uncertain identity, and adverse reactions.⁴

For example, Astavarga drugs such as Meda, Mahameda, Jivaka, and Kakoli are now rare and are substituted with Shatavari, Vidarikanda, and Ashwagandha.⁴

In certain conditions such as pregnancy, Vasa is avoided due to abortifacient properties and replaced with safer alternatives like Ashoka.⁶

TYPES OF SUBSTITUTION

Substitution may occur between different species (Tribulus terrestris and Pedalium murex), within the same family (Datura metel and Datura stramonium), or using different plant parts (root vs whole plant of Sida cordifolia).⁷

APAMISHRANA DRAVYA (ADULTERATION)

Apamishrana means mixing or aggregation. Adulteration refers to intentional or unintentional mixing of inferior substances with genuine drugs.⁸

Methods include deterioration, admixture, sophistication, substitution with inferior drugs, artificial substitution, and spoilage.⁸

DIFFERENCE BETWEEN SUBSTITUTION AND ADULTERATION

Substitution is scientific, therapeutically justified, and conservational in approach. Adulteration is unethical, profit-driven, and compromises safety and efficacy.⁹



QUALITY CONTROL AND PREVENTION

WHO recommends strict quality control and rejection of raw materials containing more than 5% foreign matter. The Drugs and Cosmetics Act 1940 provides legal provisions against adulteration.¹⁰

CONCLUSION

Abhava Pratinidhi Dravya reflects the scientific flexibility of Ayurveda in addressing drug scarcity while maintaining therapeutic integrity. Conversely, adulteration undermines drug safety and must be prevented through strict quality control, regulatory enforcement, and pharmacognostical evaluation.

REFERENCES

1. Agnivesha. *Charaka Samhita*. Varanasi: Chaukhambha Sanskrit Series; 2014.
2. *Shabda Kalpa Druma*. Varanasi: Chaukhambha Sanskrit Series; 2009.
3. Vagbhata. *Ashtanga Hridaya*. Varanasi: Chaukhambha Orientalia; 2016.
4. Bhavamishra. *Bhavaprakasha Nighantu*. Varanasi: Chaukhambha Bharati Academy; 2015.
5. Govinda Das Sen. *Bhaishajya Ratnavali*. Varanasi: Chaukhambha Orientalia; 2014.
6. Poornima B. *Adulteration and substitution in herbal drugs*. *Int J Res Ayurveda Pharm*. 2010;1(1):8-12.
7. Kirtikar KR, Basu BD. *Indian Medicinal Plants*. Dehradun: International Book Distributors; 2011.
8. Kokate CK, Purohit AP, Gokhale SB. *Pharmacognosy*. Pune: Nirali Prakashan; 2015.
9. API. *Ayurvedic Pharmacopoeia of India*. Government of India; 2007.
10. Government of India. *Drugs and Cosmetics Act*. New Delhi; 1940.
11. World Health Organization. *Quality control methods for medicinal plant materials*. Geneva: WHO; 2011.